

SOHO for the MENA Region

September 25th, 26th & 27th, 2025 –AL HABTOOR CITY BEIRUT.

Day 1 : September 25th, 2025

1245-1300 Welcome Notes

1300-1400 Pharma symposium (J&J CLL) (Elias Jabbour, MD)

Session 1 - MM

1400-1430 Frontline therapy in fit patients (Rachid Baz, MD)

1430-1500 Frontline therapy in unfit patients (Thierry Facon, MD)

1500-1530 Management of R-R MM; Bispecifics; CARTs (Jean El- Cheikh, MD)

1530-1545 Q&A

1545-1615 Coffee break

Session 2: Lymphoma 1

1615 – 1645 Updates on CAR T-cell therapy and BiTEs ADCs in Lymphoma (Anna Sureda, MD)

1645 – 1715 Updates on T-cell lymphoma (Gandhi Damaj, MD)

1715-1745 Updates on treatment of Hodgkin lymphoma (Georges Chahine, MD)

1745-1815 Hematopoietic stem cell transplantation for Hodgkin Lymphoma (Ali Bazarbachi, MD)

1815-1830 Q&A

1830-1900 Pharma symposium

Day 2 : September 26th, 2025

Session 3 - ALL

900-920 Optimizing Philadelphia-positive ALL therapy (Elias Jabbour, MD)

920-940 Frontline ALL therapy (Hagop Kantarjian, MD)

940-1000 Management of ETP-ALL and Ph-like ALL (Nitin Jain, MD)

1000-1020 Later-line therapies in ALL (Elias Jabbour, MD)

1020-1030 Q&A

1030-1045 Coffee break

Session 4: AML

1045-1115 Frontline therapy of younger/fit AML (Courtney DiNardo, MD)

1115-1145 Frontline therapy in older/unfit AML (Tapan Kadia, MD)

1145-1205 Later-line and novel targeted therapy in AML; novel combinations (Naval Daver, MD)

1205-1220 Menin inhibitors in acute leukemia (Ghayyas Issa, MD)

1220-1235 Allo HSCT in AML (Iman Abu Dalle, MD)

1235-1305 Pharma Symposium J&J (MM)

1305-1325 Q&A

1325-1430 Lunch Break

Session 5: MDS

1430-1450 Management of low-risk MDS (Rami Komrokji, MD)

1450-1510 Management of high-risk MDS (Amer Zeidan, MD)

1510-1530 allogeneic stem cell transplantation in MDS and aplastic anemia (TBA)

1530-1540 Q&A

1540-1600 Coffee break

Session 6: CLL

1600-1630 Optimizing frontline CLL therapy (Nitin Jain, MD)

1630-1700 Later line therapies in CLL (Ahmad Al Huraiji, MD)

1700-1720 The evolving landscape of prognostic models in CLL (Ahmad Ibrahim, MD)

1720-1730 Q&A

1730-1800/1830 Pharma Symposium

Session 7: Biology

1830-1850 Integrated approach to evaluation Molecular abnormalities in AML-implications (Sanam Loghavi, MD)

1850-1910 MRD assessment in hematologic malignancies (Rami Mahfouz, MD)

1910-1925 Q&A

Day 3 : September 27th,2025

815-915 Meet the expert sessions

Session 8: Lymphoma 2

915-935 Updates on follicular lymphoma (Gilles Salles, MD)

935-955 Updates on mantle cell lymphoma (Olivier Hermine, MD)

955-100 Q&A

1000-1015 Coffee break

1015-1045 Pharma Symposium

Session 9: CML – MPN

1045-1115 Optimizing therapies in MF (Ibrahim Yakoub Agha, MD)

1115-1145 How I treat PV (Rami Komrokji, MD)

1145-1215 Frontline therapy of CML; TFR (Giuseppe Saglio, MD)

1215-1245 Pharma symposium J&J (MM)

1245-1305 Q&A

1305-1320 Closing ceremony